| KRYS Stock | | | USD 156.07 0.23 0.15% |
Krystal Biotech Price To Sales Ratio yearly trend continues to be comparatively stable with very little volatility. Price To Sales Ratio will likely drop to 72.59 in 2025.
Check out the analysis of
Krystal Biotech Correlation against competitors.
For more information on how to buy Krystal Stock please use our
How to Invest in Krystal Biotech guide.
Latest Krystal Biotech's Price To Sales Growth Pattern
Below is the plot of the Price To Sales Ratio of Krystal Biotech over the last few years. Price to Sales Ratio is figured by comparing Krystal Biotech stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Krystal Biotech sales, a figure that is much harder to manipulate than other Krystal Biotech multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Krystal Biotech's Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Krystal Biotech's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 18.96 X | 10 Years Trend | | |
Krystal Price To Sales Regression Statistics
| Arithmetic Mean | 157.58 |
| Geometric Mean | 134.41 |
| Coefficient Of Variation | 51.37 |
| Mean Deviation | 77.73 |
| Median | 226.68 |
| Standard Deviation | 80.96 |
| Sample Variance | 6,554 |
| Range | 160 |
| R-Value | (0.85) |
| Mean Square Error | 1,903 |
| R-Squared | 0.73 |
| Significance | 0.000026 |
| Slope | (14.52) |
| Total Sum of Squares | 98,312 |
Krystal Price To Sales History
| 2025 | 72.59 | |
| 2024 | 76.41 | |
| 2019 | 66.45 | |
About Krystal Biotech Financial Statements
Krystal Biotech shareholders use historical fundamental indicators, such as Price To Sales, to determine how well the company is positioned to perform in the future. Although Krystal Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in Krystal Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on Krystal Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our
fundamental analysis page.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to
measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to
predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.